Compare
U S Physical Therapy Inc vs Pennant Group, Inc. vs InnovAge Holding Corp. vs GeneDx Holdings Corp.
| Latest fiscal year | U S Physical Therapy Inc USPH | Pennant Group, Inc. PNTG | InnovAge Holding Corp. INNV | GeneDx Holdings Corp. WGS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | $780.99M | $947.71M | $989.71M | $427.54M |
| Revenue growth (YoY) | +16.3% | +36.3% | +15.9% | +40.0% |
| Gross margin | 19.2% | n/a | 23.0% | 69.7% |
| Operating margin | 11.1% | 5.5% | 0.3% | -3.1% |
| Net margin | 5.1% | 3.1% | -0.3% | -4.9% |
| Net income | $39.58M | $29.58M | -$2.54M | -$21.02M |
| EPS (Diluted) | $1.42 | $0.84 | -$0.02 | -$0.73 |
| Operating cash flow | $75.06M | $48.29M | $64.71M | $33.28M |
| Free cash flow | $60.99M | $36.26M | $50.41M | $14.26M |
| Cash & equivalents | $35.57M | n/a | $97.89M | $105.00M |
| Total assets | $1.20B | $968.18M | $557.39M | $523.71M |
| Total liabilities | $433.81M | $593.93M | $288.62M | $215.53M |
| Shareholders' equity | $476.89M | $374.25M | $235.60M | $308.18M |
| Return on year-end equity | 8.3% | 7.9% | -1.1% | -6.8% |
| Shares outstanding | n/a | 34.63M | 136.02M | 29.25M |
Revenue, most recent five fiscal years
| Fiscal year | U S Physical Therapy Inc | Pennant Group, Inc. | InnovAge Holding Corp. | GeneDx Holdings Corp. |
|---|---|---|---|---|
| Latest | $780.99M Ended 2025-12-31 | $947.71M Ended 2025-12-31 | $989.71M Ended 2026-06-30 | $427.54M Ended 2025-12-31 |
| 1 year earlier | $671.35M Ended 2024-12-31 | $695.24M Ended 2024-12-31 | $853.70M Ended 2025-06-30 | $305.45M Ended 2024-12-31 |
| 2 years earlier | $604.80M Ended 2023-12-31 | $544.89M Ended 2023-12-31 | $763.86M Ended 2024-06-30 | $202.57M Ended 2023-12-31 |
| 3 years earlier | $553.14M Ended 2022-12-31 | $473.24M Ended 2022-12-31 | $688.09M Ended 2023-06-30 | $234.69M Ended 2022-12-31 |
| 4 years earlier | $495.02M Ended 2021-12-31 | $439.69M Ended 2021-12-31 | $698.64M Ended 2022-06-30 | $212.19M Ended 2021-12-31 |